Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04720196
Other study ID # JagiellonianU63
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 25, 2021
Est. completion date September 21, 2023

Study information

Verified date September 2023
Source Jagiellonian University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vasculitic neuropathy (VN) results from inflammation and destruction of the walls of predominantly small vessels with subsequent ischemic damage of peripheral nerves. VN is painful in vast majority of patients and the pain is intractable with pharmacotherapy in about 40% of cases. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.


Description:

Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves. Neural damage may or may not coexist with the damage of other organs. Examples of conditions associated with VN include diabetes, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss), granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, systemic lupus erythematosus and others. VN is painful in about 80% of patients of whom 40% suffer from the pain intractable with pharmacological therapy. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity. In this method, series of magnetic stimuli are delivered to the cerebral cortex, where they turn to electric current and depolarize repetitively the targeted neurons. If the stimulation is repeated during subsequent days it is capable to modify the activity of targeted cortical area for weeks or even months and by this way to achieve therapeutic effect. rTMS is widely regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date September 21, 2023
Est. primary completion date September 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of vasculitic neuropathy - Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week - Score of 30 milimeter or more on the 100 milimeter visual analog scale of pain intensity at inclusion Exclusion Criteria: - Severe depression - Personality disorders and other psychiatric conditions, which could disturb the participation in the study - Cognitive deficits, which could disturb the participation in the study - Contraindications for rTMS as listed by the Guidelines of the International Federation of Clinical Neurophysiology (Rossi et al. 2009) i.e. seizure in the past, epilepsy, presence of magnetic material in the reach of magnetic field, pregnancy, likelihood to get pregnant, intracranial electrodes, cardiac pacemaker or intracardiac lines, frequent syncopes

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Active repetitive transcranial magnetic stimulation
High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
Sham repetitive transcranial magnetic stimulation
Sham stimulation to mimic the high frequency rTMS over the primary motor area.

Locations

Country Name City State
Poland Jagiellonian University Medical College, Department of Neurology Kraków

Sponsors (1)

Lead Sponsor Collaborator
Jagiellonian University

Country where clinical trial is conducted

Poland, 

References & Publications (1)

Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Numeric Pain Severity Scale after rTMS Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Primary Numeric Pain Severity Scale First Follow Up Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Primary Numeric Pain Severity Scale Second Follow Up Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Primary Visual Analog Scale of Pain Severity An analog scale of the length of 100 milimeter. Total score of 100, with higher scores representing more severe pain. Change through the study. Through study completion, an average of 10 weeks
Secondary Hospital Anxiety and Depression Scale after rTMS Total score 64, with higher scores representing more severe depression. Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Hospital Anxiety and Depression Scale First Follow Up Total score 64, with higher scores representing more severe depression. Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Hospital Anxiety and Depression Scale Second Follow Up Total score 64, with higher scores representing more severe depression. Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary 36-Item Short Form Health Survey after rTMS Total score, range 0 to 800, with lower values representing a worse outcome. Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary 36-Item Short Form Health Survey First Follow Up Total score, range 0 to 800, with lower values representing a worse outcome. Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary 36-Item Short Form Health Survey Second Follow Up Total score, range 0 to 800, with lower values representing a worse outcome. Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function after rTMS Total score, range 0 to 100, with lower values representing a worse outcome. Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function First Follow Up Total score, range 0 to 100, with lower values representing a worse outcome. Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function Second Follow Up Total score, range 0 to 100, with lower values representing a worse outcome. Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Assessment of pain threshold to electric stimuli after rTMS Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful. Change from baseline pain threshold to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Assessment of sensory threshold to electric stimuli after rTMS Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation. Change from baseline sensory threshold to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Assessment of pain threshold to electric stimuli First Follow Up Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful. Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Assessment of sensory threshold to electric stimuli First Follow Up Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation. Change from baseline sensory threshold to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Assessment of pain threshold to electric stimuli Second Follow Up Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful. Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Assessment of sensory threshold to electric stimuli Second Follow Up Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation. Change from baseline sensory threshold to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Assessment of cold sensation threshold to cold stimuli after rTMS Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold. Change from baseline cold sensation threshold to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Assessment of pain threshold to cold temeprature stimuli after rTMS Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Assessment of cold sensation threshold to cold temeprature stimuli First Follow Up Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold. Change from baseline cold sensation threshold to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Assessment of pain threshold to cold temeprature stimuli First Follow Up Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Assessment of cold sensation threshold to cold temeprature stimuli Second Follow Up Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold. Change from baseline cold sensation threshold to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Assessment of pain threshold to cold temeprature stimuli Second Follow Up Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Assessment of warmth sensation threshold to warm temeprature stimuli after rTMS Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth. Change from baseline warmth sensation threshold to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Assessment of pain threshold to warm temeprature stimuli after rTMS Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Assessment of warmth sensation threshold to warm temeprature stimuli First Follow Up Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth. Change from baseline warmth sensation threshold to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Assessment of pain threshold to warm temeprature stimuli First Follow Up Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Assessment of warmth sensation threshold to warm temeprature stimuli Second Follow Up Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth. Change from baseline warmth sensation threshold to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Assessment of pain threshold to warm temeprature stimuli Second Follow Up Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Bilateral Dynamometric Assessment of the strength of the index finger flexion after rTMS Change from baseline strength of the index finger flexion to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Bilateral Dynamometric Assessment of the strength of the foot extension after rTMS Change from baseline strength of the foot extension to the measurement taken after finishing rTMS. Before rTMS, immediately after (on same day) finishing rTMS.
Secondary Bilateral Dynamometric Assessment of the strength of the index finger flexion First Follow Up Change from baseline strength of the index finger flexion to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Bilateral Dynamometric Assessment of the strength of the foot extension flexion First Follow Up Change from baseline strength of the foot extension to the measurement taken two weeks after finishing rTMS. Before rTMS, two weeks after finishing rTMS
Secondary Bilateral Dynamometric Assessment of the strength of the index finger flexion Second Follow Up Change from baseline strength of the index finger flexion to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
Secondary Bilateral Dynamometric Assessment of the strength of the foot extension Second Follow Up Change from baseline strength of the index foot extension to the measurement taken four weeks after finishing rTMS. Before rTMS, four weeks after finishing rTMS
See also
  Status Clinical Trial Phase
Recruiting NCT06040567 - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study